CYCN CYCN
Company Profile ↓Company Overview
CYCN (CYCN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 30.7% per year over the last five years.
Revenue has grown at a 91.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.07M (+3.7% YoY); net profit $-3.53M.
- Trailing 12 Months Year-on-year growth — revenue +3.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.1%, profit CAGR 30.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.14% |
| 1 Year: | 3.70% |
Compounded Profit Growth
| 5 Years: | 30.67% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +27.42% |
| 6 Months: | +186.29% |
| 3 Months: | +12.70% |
| 1 Month: | +2.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.1% over 5 years.
- Profit CAGR of 30.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 44.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.63M | 1.40M | 1.01M | 749.00K | 400.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -25.28M | -29.78M | -29.29M | -37.38M | -33.05M | -28.02M | -20.59M | -19.67M | -21.78M | -13.39M | -16.18M | -11.29M | -12.98M | -13.43M | -4.52M | -3.27M | -1.86M | -6.01M | -1.62M | -1.38M | -1.13M | -1.46M | -1.67M | -1.01M | -3.21M |
| Net Income | -25.28M | -29.78M | -29.29M | -37.38M | -32.25M | -27.32M | -20.23M | -19.53M | -18.81M | -6.95M | -16.18M | -11.29M | -12.98M | -13.39M | -10.50M | -6.95M | -4.18M | 7.57M | -1.54M | -1.32M | -723.00K | -1.43M | -324.00K | -976.00K | -3.18M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.45 | -0.26 | -0.30 | -6.16 | -4.83 | -3.20 | -1.83 | 2.72 | -0.62 | -0.53 | -0.29 | -0.56 | -0.11 | -0.30 | -0.76 |
| R&D Expense | 21.51M | 22.25M | 21.50M | 26.40M | 25.76M | 22.30M | 16.82M | 13.79M | 13.70M | 8.09M | 12.05M | 7.03M | 9.74M | 10.22M | 1.41M | 572.00K | 339.00K | 580.00K | 44.00K | 105.00K | 81.00K | 36.00K | 56.00K | 348.00K | 730.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 4.51M | 2.30M | - | 297.00K | 0 | 2.00M | 2.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 18.84M | 9.65M | 5.63M | 7.05M |
| Operating Income | -115.25M | -125.04M | -81.27M | - | -18.54M | -9.65M | -3.63M | -4.97M |
| EBITDA | - | - | - | - | -18.48M | -9.65M | -3.63M | -4.97M |
| Interest Expense | - | - | - | 16.00K | - | - | - | - |
| Pretax Income | - | - | - | - | -18.25M | -12.59M | -3.06M | -3.53M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -115.25M | -123.01M | -77.80M | - | -44.08M | -5.26M | -3.06M | -3.53M |
| Diluted EPS | - | - | - | - | -20.28 | -2.25 | -1.21 | -1.11 |
| R&D Expense | 87.72M | 95.14M | 56.41M | 37.64M | 5.98M | 1.51M | 286.00K | 959.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.40M | 186.48M | 115.38M | 59.33M | 18.08M | 13.37M | 9.57M | 9.98M |
| Total Equity | -8.57M | -10.45M | 97.73M | 59.49M | 48.25M | 10.45M | 11.29M | 8.85M | 9.09M |
| Cash & Equivalents | - | - | 94.89M | 54.40M | 53.96M | 13.38M | 7.57M | 3.23M | 3.24M |
| Current Liabilities | - | 17.85M | 18.25M | 16.95M | 11.09M | 7.63M | 2.09M | 725.00K | 900.00K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -97.50M | -102.22M | -72.49M | -36.52M | -40.61M | -21.25M | -4.33M | -3.31M |
| Investing Cash Flow | -3.44M | -6.71M | 18.00K | 1.46M | 0 | 10.40M | 0 | - |
| Financing Cash Flow | 100.94M | 211.57M | 28.09M | 30.79M | 29.00K | 5.02M | 0 | 3.32M |
| Capital Expenditure | -3.44M | -6.89M | -1.52M | -7.00K | -0 | - | - | - |
| Free Cash Flow | -100.94M | -109.10M | -74.01M | -36.52M | -40.61M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -2,774.3% | -3,539.4% | - | -6,242.4% | - | -181.4% | -239.8% |
| Net Margin % | - | -2,729.3% | -3,388.6% | - | -14,841.1% | - | -152.8% | -170.1% |
| ROE % | 1,103.4% | -125.9% | -130.8% | - | -421.7% | -46.6% | -34.5% | -38.8% |
| ROCE % | 1,103.4% | -74.3% | -82.6% | - | -177.4% | -85.5% | -41.0% | -54.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CYCN
Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNelo4ZnVnSDdINFlaUE9Va0FwV3V0UGxFejdyNjFLWGl6TXotZk5TTEcweTI1YzktUGVPQzdlekcyMGVhNnh1ZmFob0tCeHZSdkRpeVluSDhzN0VGWDVyMHI1dnRCTG9acnBZVjZNamJNUWF0SkpIUzFPUHVhSGJnM3ZuUDF4cnoyV1hhck…
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNUHVCTVBCM0xfWG1nZHpnZ05pNk1kS3cyUUFZZ0RWXzVtcXVpT3dJUFFMcXBIVVN2LVlGVnI3YTdJdi1qbjZJcUJDbXA2YUFpZGZITHZwYUV1cGozb0dqRzNidkwyX3I5dzBkYmVHODNyRUpGQWQ5UVNUaTV4Sk5pUVQ0YmdrWkpQZDlxeF…
CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQcUV6TV9VVFdXendxcmlzc2dTR3JIRnFxSkl4UUJUaUpWSktJWVBaTjY4ajgtRFZ4T3NzWTJNdUx1U2tXeFduYjJ0RWgxXzhwMzFVWkJ3V1JBdVItREpCNjVTMHM5WXREZHhOQkM2UlF1SlY1TkNxVThHWW1TdERHcVRTQ1dhQWtGR0wtNn…
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHpldnBQOGlIV3k2QVkzNThWR0gyWl9nMTE5X2dqQVRoUmNtRHlqMWlXSVhmakc0ZXlGd2tNcGVVMUpuN3BzOTRmajhtNkFiblZHN1JWMUdXUkZhS3VBaFZzcWZlNi1RaE5PVE1lVUFXTFZ1Mm5yc1FxYmtFS3BsbzFwSDBWb3Y0WlJ2WF…
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9YQTMzRVJTVlN0bVdYa0JjRnAweHYzZWlZbFd1QWdmT3BhSURDZkxzejJvdVhzdlplMS1tUl9zRWo2ei1YcTEzQWg0Y1FhNHZlNDh2ZGRHTEdYbENH?oc=5" target="_blank">CYCN | Cyclerion Therapeutics, Inc. Common …
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9NM1RNaHYtSUE3b3BaajVOQ3NOQzNPYVVodmNJS0hSU0tBajF1U2dybW9DcXdzZnhzTTlzcHdzSmRrdmFWeEtpNDBxWm83T0pLbXBKR0szSy1OLTdkYVhrTnluUjNKRkFuS2lfSXdaSVZiXzlrSVJJ?oc=5" target="_blank">Cycleri…
CYCN — Frequently Asked Questions
What is the current share price of CYCN?
As of 2026-08-05 17:25 PDT, CYCN trades at $3.55 on NASDAQ/NYSE. Its 52-week range is $1.08 to $6.38.
What is the P/E ratio of CYCN?
CYCN trades at a trailing price-to-earnings (P/E) ratio of -3.20.
What is the return on equity (ROE) of CYCN?
CYCN has a return on equity (ROE) of -38.83%. Its return on capital employed (ROCE) is -54.74%.
Is CYCN a good stock to buy?
This page provides a data-driven analysis of CYCN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.